New cocktail aims to Deep-Freeze myeloma

NCT ID NCT04268498

Ongoing Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding daratumumab to a three-drug regimen (carfilzomib, lenalidomide, dexamethasone) works better than the three drugs alone for people newly diagnosed with multiple myeloma. About 310 participants will be randomly assigned to one of the treatments. The main goal is to see if the combination leads to less detectable cancer after eight cycles of therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab, carfilzomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this could offer a more effective initial treatment for multiple myeloma, potentially leading to longer remission and better disease control.
What could go wrong: This is a Phase 2 trial, so results are still early. The combination may cause more side effects, and it's not yet proven to be better than current standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Huntsman Cancer Institue

Salt Lake City, Utah, 84113, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612-9497, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Stony Brook University

Stony Brook, New York, 11794, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.